Results 181 to 190 of about 18,846,273 (226)
Some of the next articles are maybe not open access.
Pharmacokinetics of intraperitoneal mitomycin C
Surgical Oncology Clinics of North America, 2003The favorable pharmacokinetics of MMC, used during intraperitoneal chemotherapy, has been reported in several studies [11-19]. A major safety issue in studies using intraperitoneal chemotherapy perfusion is the resulting systemic drug exposure. The AUCplasma is determined by the dose, the clearance, and the fraction absorbed from the peritoneal cavity.
S, van Ruth +2 more
openaire +2 more sources
Bioactivation and Resistance to Mitomycin C
2004Publisher Summary This chapter analyzes the bioactivation and resistance of tumor cells to mitomycin C (MC). MC is a naturally occurring antibiotic that was isolated originally from the microorganism Streptomyces caspitosus . MC exerts its antitumor activity primarily by damaging DNA through both monofunctional and bifunctional alkylations (cross ...
Helen A, Seow +3 more
openaire +2 more sources
Cancer chemotherapy and biological response modifiers, 1994
In conclusion, recent work has highlighted the fact that NSCLCs have elevated levels of NQO1 activity and that such an increase represents an excellent target for therapeutic exploitation. The 5-year survival rate seen with lung cancer is dismal and there is a high number of cancer deaths associated with this disease each year.
N W, Gibson, D, Ross
openaire +1 more source
In conclusion, recent work has highlighted the fact that NSCLCs have elevated levels of NQO1 activity and that such an increase represents an excellent target for therapeutic exploitation. The 5-year survival rate seen with lung cancer is dismal and there is a high number of cancer deaths associated with this disease each year.
N W, Gibson, D, Ross
openaire +1 more source